17-07-2025
HER2+ Gastric Cancer Pipeline Appears Promising With 20+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment
DelveInsight's, 'HER2 Positive Gastric Cancer Pipeline Insight' report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in HER2 Positive Gastric Cancer pipeline landscape. It covers the HER2 Positive Gastric Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Gastric Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in HER2 Positive Gastric Cancer Research. Learn more about our innovative pipeline today! @ HER2 Positive Gastric Cancer Pipeline Outlook
Key Takeaways from the HER2 Positive Gastric Cancer Pipeline Report
In July 2025, AstraZeneca announced a study is to assess the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.
In July 2025, Daiichi Sankyo conducted a clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus trastuzumab plus pembrolizumab as first-line therapy in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS ≥1 gastric or GEJ cancer in the Main Cohort. An Exploratory Cohort will also be evaluated to assess the efficacy and safety of T-DXd plus a fluoropyrimidine versus SoC chemotherapy plus trastuzumab in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS
DelveInsight's HER2 Positive Gastric Cancer pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for HER2 Positive Gastric Cancer treatment.
The leading HER2 Positive Gastric Cancer Companies such as Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.
Promising HER2 Positive Gastric Cancer Therapies such as YH32367, BI-1607, Trastuzumab, BDC-1001, Nivolumab, KN026, BNT323, and others.
Stay informed about the cutting-edge advancements in HER2 Positive Gastric Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ HER2 Positive Gastric Cancer Clinical Trials Assessment
HER2 Positive Gastric Cancer Emerging Drugs
SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
SHR-A1811 is a novel anti-HER2 antibody-drug conjugate (ADC) that features an optimized molecular design to enhance plasma stability and bystander effect. Hengrui Pharma is currently conducting more than 10 clinical studies of SHR-A1811 from phase 1 to phase 3 to evaluate its safety and efficacy as single agent or combination therapy in a wide variety of cancer indications. Currently, the drug is in Phase III stage of its development for the treatment of HER2-positive Gastric Cancer.
Cinrebafusp alfa: Pieris Pharmaceuticals
Cinrebafusp alfa (PRS-343) is a 4-1BB/HER2 fusion protein comprising 4-1BB-targeting Anticalin proteins and a HER2-targeting antibody. The drug candidate is currently in phase 2 development for the treatment of HER2-expressing solid tumors. In phase 1 studies, cinrebafusp alfa has shown an acceptable safety profile at all doses tested with no dose-limiting toxicities. The bispecific also showed a dose response and a 4-1BB-driven mechanism of action based on clinical benefit and pharmacodynamic correlates. Currently, the drug is in Phase II stage of its development for the treatment of HER2-positive Gastric Cancer.
BI-1607 is an FcγRIIB-blocking antibody that differs from BI-1206 (BioInvent's clinical-stage FcγRIIB antibody) in that it has been engineered for reduced Fc-binding to FcγRs. Preclinical proof-of-concept data indicate that combined treatment with BI-1607 may both enhance efficacy of current anti-HER2 regimens and increase response rates in patients no longer responding to anti-HER2-directed therapies such as trastuzumab. Currently, the drug is in Phase I/II stage of its development for the treatment of HER2-positive Gastric Cancer.
The HER2 Positive Gastric Cancer pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of HER2 Positive Gastric Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2 Positive Gastric Cancer Treatment.
HER2 Positive Gastric Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
HER2 Positive Gastric Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HER2 Positive Gastric Cancer market.
Learn more about HER2 Positive Gastric Cancer Drugs opportunities in our groundbreaking HER2 Positive Gastric Cancer Research and development projects @ HER2 Positive Gastric Cancer Unmet Needs
HER2 Positive Gastric Cancer Companies
Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.
HER2 Positive Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
Oral
Intravenous
Subcutaneous
Parenteral
Topical
HER2 Positive Gastric Cancer Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Discover the latest advancements in HER2 Positive Gastric Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ HER2 Positive Gastric Cancer Market Drivers and Barriers, and Future Perspectives
HER2 Positive Gastric Cancer Companies and Therapies
BDC-1001: Bolt Therapeutics Inc.
KN026: Shanghai JMT-Bio Inc.
YH32367: Yuhan Corporation
Margetuximab: MacroGenics
Zanidatamab: Jazz Pharmaceuticals
Scope of the HER2 Positive Gastric Cancer Pipeline Report
Coverage- Global
HER2 Positive Gastric Cancer Companies- Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.
HER2 Positive Gastric Cancer Therapies- YH32367, BI-1607, Trastuzumab, BDC-1001, Nivolumab, KN026, BNT323, and others.
HER2 Positive Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
HER2 Positive Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of HER2 Positive Gastric Cancer Pipeline on our website @ HER2 Positive Gastric Cancer Drugs and Companies
Table of Content
Introduction
Executive Summary
HER2-positive Gastric Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
HER2-positive Gastric Cancer– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Cinrebafusp alfa: Pieris Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
BI-1607: BioInvent International
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
HER2-positive Gastric Cancer Key Companies
HER2-positive Gastric Cancer Key Products
HER2-positive Gastric Cancer- Unmet Needs
HER2-positive Gastric Cancer- Market Drivers and Barriers
HER2-positive Gastric Cancer- Future Perspectives and Conclusion
HER2-positive Gastric Cancer Analyst Views
HER2-positive Gastric Cancer Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
